Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis

被引:143
作者
Freeman, Tom P. [1 ,2 ]
Craft, Sam [1 ,2 ]
Wilson, Jack [3 ]
Stylianou, Stephan [2 ]
ElSohly, Mahmoud [4 ,5 ]
Di Forti, Marta [6 ]
Lynskey, Michael T. [2 ]
机构
[1] Univ Bath, Dept Psychol, Addict & Mental Hlth Grp AIM, 10 West,Room 3-47, Bath 2 7AY, Avon, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, Natl Addict Ctr, London, England
[3] Univ Sydney, Matilda Ctr Res Mental Hlth & Subst Use, Sydney, NSW, Australia
[4] Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA
[5] Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA
[6] Kings Coll London, Social Genet & Dev Psychiat Ctr, London, England
关键词
Cannabis; Cannabis resin; CBD; potency; Sinsemilla; THC; POTENCY TRENDS; DELTA(9)-TETRAHYDROCANNABINOL; HETEROGENEITY; ASSOCIATIONS; PSYCHOSIS; PRODUCTS; SMOKING; MARKET; USERS;
D O I
10.1111/add.15253
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and aims Cannabis products with high delta-9-tetrahydrocannabinol (THC) concentrations carry an increased risk of addiction and mental health disorders, while it has been suggested that cannabidiol (CBD) may moderate the effects of THC. This study aimed to systematically review and meta-analyse changes in THC and CBD concentrations in cannabis over time (PROSPERO registration: CRD42019130055). Design Embase, MEDLINE (R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily, Global Health, PsycINFO and Scopus were searched from inception to 27/03/2019 for observational studies reporting changes in mean THC and/or CBD concentration in cannabis over at least three annual time points. Searches and extraction were conducted by two independent reviewers. Random effects meta-regression models estimated annual changes in THC and CBD for each product within each study; these estimates were pooled across studies in random effects models. Results We identified 12 eligible studies from the USA, UK, Netherlands, France, Denmark, Italy and New Zealand. For all herbal cannabis, THC concentrations increased by 0.29% each year (95% CI: 0.11, 0.47), P < 0.001 based on 66 747 cannabis samples from eight studies, 1970-2017. For cannabis resin, THC concentrations increased by 0.57% each year (95% CI: 0.10, 1.03), P = 0.017 based on 17 371 samples from eight studies, 1975-2017. There was no evidence for changes in CBD in herbal cannabis [-0.01% (95% CI: -0.02, 0.01), P = 0.280; 49 434 samples from five studies, 1995-2017] or cannabis resin [0.03% (95% CI: -0.11, 0.18), P = 0.651; 11 382 samples from six studies, 1992-2017]. Risk of bias was low apart from non-random sampling in most studies. There was evidence of moderate to substantial heterogeneity. Conclusions Concentrations of delta-9-tetrahydrocannabinol (THC) in international cannabis markets increased from 1970 to 2017 while cannabidiol (CBD) remained stable. Increases in THC were greater in cannabis resin than herbal cannabis. Rising THC in herbal cannabis was attributable to an increased market share of high-THC sinsemilla relative to low-THC traditional herbal cannabis.
引用
收藏
页码:1000 / 1010
页数:11
相关论文
共 59 条
  • [1] [Anonymous], 2018, PSYCHOL MED
  • [2] Higher average potency across the United States is associated with progression to first cannabis use disorder symptom
    Arterberry, Brooke J.
    Padovano, Hayley Treloar
    Foster, Katherine T.
    Zucker, Robert A.
    Hicks, Brian M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2019, 195 : 186 - 192
  • [3] Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
    Bisogno, T
    Hanus, L
    De Petrocellis, L
    Tchilibon, S
    Ponde, DE
    Brandi, I
    Moriello, AS
    Davis, JB
    Mechoulam, R
    Di Marzo, V
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) : 845 - 852
  • [4] The neuropsychopharmacology of cannabis: A review of human imaging studies
    Bloomfield, Michael A. P.
    Hindocha, Chandni
    Green, Sebastian F.
    Wall, Matthew B.
    Lees, Rachel
    Petrilli, Katherine
    Costello, Harry
    Ogunbiyi, M. Olabisi
    Bossong, Matthijs G.
    Freeman, Tom P.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2019, 195 : 132 - 161
  • [5] Heterogeneity in the composition of marijuana seized in California
    Burgdorf, James Richard
    Kilmer, Beau
    Pacula, Rosalie Liccardo
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2011, 117 (01) : 59 - 61
  • [6] Cascini Fidelia, 2012, Curr Drug Abuse Rev, V5, P32
  • [7] Big data on a big new market: Insights from Washington State's legal cannabis market
    Caulkins, Jonathan P.
    Bao, Yilun
    Davenport, Steve
    Fahli, Imane
    Guo, Yutian
    Kinnard, Krista
    Najewicz, Mary
    Renaud, Lauren
    Kilmer, Beau
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 57 : 86 - 94
  • [8] New trends in cannabis potency in USA and Europe during the last decade (2008-2017)
    Chandra, Suman
    Radwan, Mohamed M.
    Majumdar, Chandrani G.
    Church, James C.
    Freeman, Tom P.
    ElSohly, Mahmoud A.
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2019, 269 (01) : 5 - 15
  • [9] Hashish revival in Morocco
    Chouvy, Pierre-Arnaud s
    Afsahi, Kenza
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2014, 25 (03) : 416 - 423
  • [10] Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence
    Craft, Sam
    Winstock, Adam
    Ferris, Jason
    Mackie, Clare
    Lynskey, Michael T.
    Freeman, Tom P.
    [J]. PSYCHOLOGICAL MEDICINE, 2020, 50 (14) : 2364 - 2373